Whitehawk Therapeutics Stock Performance
| WHWK Stock | 2.57 0.07 2.65% |
On a scale of 0 to 100, Whitehawk Therapeutics holds a performance score of 6. The firm maintains a market beta of 1.25, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Whitehawk Therapeutics will likely underperform. Please check Whitehawk Therapeutics' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Whitehawk Therapeutics' historical returns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Whitehawk Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating basic indicators, Whitehawk Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.65) | Five Day Return (4.10) | Year To Date Return 5.33 | Ten Year Return (97.14) | All Time Return (97.14) |
Last Split Factor 1:15 | Last Split Date 2021-08-27 |
1 | Head-To-Head Analysis Intellipharmaceutics International vs. Whitehawk Therapeutics | 11/05/2025 |
2 | Whitehawk Therapeutics Releases Quarterly Earnings Results, Beats Estimates By 0.25 EPS - MarketBeat | 11/07/2025 |
3 | Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London | 11/11/2025 |
4 | Will Whitehawk Therapeutics Inc. stock deliver stable dividends - 2025 Biggest Moves AI Driven Stock Reports - newser.com | 11/19/2025 |
5 | How Whitehawk Therapeutics Inc. stock trades after earnings - 2025 Risk Factors Safe Capital Growth Trade Ideas - Newser | 12/02/2025 |
6 | Acerus Pharmaceuticals and Whitehawk Therapeutics Head-To-Head Contrast | 12/09/2025 |
7 | Acquisition by Bryan Ball of 366532 shares of Whitehawk Therapeutics, at 1.7 subject to Rule 16b-3 | 12/22/2025 |
8 | Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 | 01/08/2026 |
| Begin Period Cash Flow | 63 M | |
| Total Cashflows From Investing Activities | 25.2 M | |
| Free Cash Flow | -61.2 M |
Whitehawk | Build AI portfolio with Whitehawk Stock |
Whitehawk Therapeutics Relative Risk vs. Return Landscape
If you would invest 210.00 in Whitehawk Therapeutics on October 15, 2025 and sell it today you would earn a total of 47.00 from holding Whitehawk Therapeutics or generate 22.38% return on investment over 90 days. Whitehawk Therapeutics is currently generating 0.5319% in daily expected returns and assumes 6.493% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Whitehawk, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Whitehawk Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Whitehawk Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Whitehawk Therapeutics, and traders can use it to determine the average amount a Whitehawk Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0819
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | WHWK | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Whitehawk Therapeutics is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Whitehawk Therapeutics by adding it to a well-diversified portfolio.
Whitehawk Therapeutics Fundamentals Growth
Whitehawk Stock prices reflect investors' perceptions of the future prospects and financial health of Whitehawk Therapeutics, and Whitehawk Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Whitehawk Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.54 | ||||
| Profit Margin | (1.09) % | ||||
| Operating Margin | (7.54) % | ||||
| Current Valuation | (43.83 M) | ||||
| Shares Outstanding | 47.13 M | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 8.26 X | ||||
| Revenue | 25.98 M | ||||
| Gross Profit | (73.45 M) | ||||
| EBITDA | (64.63 M) | ||||
| Net Income | (63.69 M) | ||||
| Total Debt | 833 K | ||||
| Book Value Per Share | 3.33 X | ||||
| Cash Flow From Operations | (59.55 M) | ||||
| Earnings Per Share | (0.64) X | ||||
| Market Capitalization | 118.76 M | ||||
| Total Asset | 70.32 M | ||||
| Retained Earnings | (332.65 M) | ||||
| Working Capital | 44.21 M | ||||
About Whitehawk Therapeutics Performance
By examining Whitehawk Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Whitehawk Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Whitehawk Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 32.28 | 26.98 | |
| Return On Tangible Assets | (1.04) | (1.09) | |
| Return On Capital Employed | (1.46) | (1.38) | |
| Return On Assets | (1.04) | (1.09) | |
| Return On Equity | (1.40) | (1.33) |
Things to note about Whitehawk Therapeutics performance evaluation
Checking the ongoing alerts about Whitehawk Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Whitehawk Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Whitehawk Therapeutics is way too risky over 90 days horizon | |
| Whitehawk Therapeutics appears to be risky and price may revert if volatility continues | |
| Whitehawk Therapeutics was previously known as AADI Old and was traded on NASDAQ Exchange under the symbol AADI. | |
| The company reported the previous year's revenue of 25.98 M. Net Loss for the year was (63.69 M) with loss before overhead, payroll, taxes, and interest of (73.45 M). | |
| Whitehawk Therapeutics generates negative cash flow from operations | |
| Whitehawk Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 67.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 |
- Analyzing Whitehawk Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Whitehawk Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Whitehawk Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Whitehawk Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Whitehawk Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Whitehawk Therapeutics' stock. These opinions can provide insight into Whitehawk Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Whitehawk Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in services. For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. If investors know Whitehawk will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Whitehawk Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
The market value of Whitehawk Therapeutics is measured differently than its book value, which is the value of Whitehawk that is recorded on the company's balance sheet. Investors also form their own opinion of Whitehawk Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Whitehawk Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Whitehawk Therapeutics' market value can be influenced by many factors that don't directly affect Whitehawk Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Whitehawk Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.